藥品參考
Gefitinib
Gefitinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 藥物類別: Oncology
- 用途: non-small cell lung cancer
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01XE02
- 常見劑型
- 錠劑
- 常見規格
- 250 mg
- 已知交互作用
- 39 (嚴重: 10 · 中度: 27 · 輕微: 2)
- 商品名
- 3
- 國家與市場
- 3
用途
作用方式
Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation and blocking downstream signaling and EGFR-dependent proliferation. It binds exon 19 deletion and L858R mutant EGFR with higher affinity than wild-type.
成人常用劑量（仿單摘要）
First-line metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations: 250 mg orally once daily with or without food until disease progression or unacceptable toxicity
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm when given to a pregnant woman; animal studies showed fetotoxicity and neonatal death at doses below the recommended human dose.
- 哺乳
- Unsafe It is not known whether excreted in human milk; present in rat milk. Advise women to discontinue breast-feeding during treatment.
已通報的副作用
- Skin reactions
- Diarrhea
- Nail disorders
- Increased ALT
- Increased AST
- Conjunctivitis, blepharitis and dry eye
禁忌症
- None.
哪些人需要特別留意
- Interstitial lung disease occurred in 1.3% of patients, with fatal cases. Withhold for worsening respiratory symptoms and discontinue if confirmed.
- Hepatotoxicity: obtain periodic liver function testing; withhold for worsening liver function; discontinue for severe hepatic impairment.
- Gastrointestinal perforation occurred in 0.1% of patients; discontinue permanently.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (39)
- Apalutamide + Gefitinib Major
- Carbamazepine + Gefitinib Major
- Dexlansoprazole + Gefitinib Major
- Esomeprazole + Gefitinib Major
- Gefitinib + Lansoprazole Major
- Gefitinib + Omeprazole Major
- Gefitinib + Pantoprazole Major
- Gefitinib + Phenytoin Major
- Gefitinib + Rabeprazole Major
- Gefitinib + Rifampicin Major
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Gefitinib 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
在網頁版免費試用 Pro+ 14 天，無需信用卡。
同類別的其他藥品
常見問題
What is Gefitinib used for?
Gefitinib is a medicine in the class oncology. It is used for Non-small cell lung cancer.
What side effects have been reported with Gefitinib?
Skin reactions, Diarrhea, Nail disorders, Increased ALT, Increased AST, Conjunctivitis, blepharitis and dry eye.
Can Gefitinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm when given to a pregnant woman; animal studies showed fetotoxicity and neonatal death at doses below the recommended human dose. Breastfeeding: Unsafe. It is not known whether excreted in human milk; present in rat milk. Advise women to discontinue breast-feeding during treatment.
What does Gefitinib interact with?
MediHelp lists 39 known interactions for Gefitinib. Major: 10 · Moderate: 27 · Minor: 2. The most serious include Apalutamide, Carbamazepine, Dexlansoprazole.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
